We are developing molecular tests designed to improve the diagnostic accuracy of cytology samples, thereby helping to increase the utility of these minimally invasive procedures as an alternative to surgical biopsy. Our Goal: Enable Doctors to Make More Informed Treatment Decisions Our Focus: Molecular Cytology
Company Growth (employees)
Type
Public
HQ
South San Francisco, US
Founded
2008
Size (employees)
216 (est)+13%
Veracyte was founded in 2008 and is headquartered in South San Francisco, US

Key People at Veracyte

Bonnie Anderson

Bonnie Anderson

Co-Founder & CEO
Shelly D. Guyer

Shelly D. Guyer

CFO
Richard Lanman

Richard Lanman

Chief Medical Officer
Giulia C. Kennedy

Giulia C. Kennedy

Chief Scientific Officer
Chris Hall

Chris Hall

Chief Commercial Officer
Robert Monroe

Robert Monroe

VP, Laboratory Operations & Medical Director

Veracyte Office Locations

Veracyte has offices in South San Francisco and Austin
South San Francisco, US (HQ)
300 6000 Shoreline Ct
Austin, US
100 12357 Riata Trace Pkwy

Veracyte Data and Metrics

Veracyte Financial Metrics

Veracyte's revenue was reported to be $65.1 m in FY, 2016 which is a 31% increase from the previous period.
$, USD

Revenue (FY, 2016)

65.1 m

Revenue growth (FY, 2015 - FY, 2016), %

31%

Gross profit (FY, 2016)

39.6 m

Gross profit margin (FY, 2016), %

61%

Net income (FY, 2016)

(31.4 m)

EBIT (FY, 2016)

(28.8 m)

Market capitalization (22-Jun-2017)

266.9 m

Closing share price (22-Jun-2017)

7.8

Cash (31-Dec-2016)

59.2 m

EV

232.6 m
Veracyte's current market capitalization is $266.9 m.
$, USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

21.9 m38.2 m49.5 m65.1 m

Revenue growth, %

75%30%31%

Cost of goods sold

12.6 m16.6 m21.5 m25.5 m

Gross profit

9.3 m21.6 m28 m39.6 m

Gross profit Margin, %

42%57%57%61%

Operating expense total

45.1 m67.2 m83 m93.9 m

EBIT

(23.2 m)(29 m)(33.5 m)(28.8 m)

EBIT margin, %

(106%)(76%)(68%)(44%)

Net Income

(25.6 m)(29.4 m)(33.7 m)(31.4 m)
$, USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

71.2 m35 m39.1 m59.2 m

Accounts Receivable

1.1 m3.1 m3.5 m8.8 m

Inventories

1.5 m1.2 m1.5 m2.1 m

Current Assets

76.4 m43.3 m47.9 m73.6 m

PP&E

3 m4.2 m10.3 m11.5 m

Goodwill

1.1 m1.1 m1.1 m

Total Assets

79.6 m64.8 m75.3 m101 m

Accounts Payable

5.3 m7.4 m5.1 m2.4 m

Total Debt

4.9 m4.9 m5 m24.9 m

Current Liabilities

15.4 m17.1 m14.7 m11.5 m

Additional Paid-in Capital

142.1 m156.4 m200 m239.6 m

Retained Earnings

(85.6 m)(115 m)(148.7 m)(180.1 m)

Total Equity

56.4 m41.4 m51.3 m59.6 m

Debt to Equity Ratio

0.1 x0.1 x0.1 x0.4 x

Debt to Assets Ratio

0.1 x0.1 x0.1 x0.2 x

Financial Leverage

1.4 x1.6 x1.5 x1.7 x
$, USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(25.6 m)(29.4 m)(33.7 m)(31.4 m)

Depreciation and Amortization

999 k1.2 m2.3 m3.5 m

Accounts Receivable

(683 k)(2 m)(558 k)(5.3 m)

Accounts Payable

3.3 m1.9 m(3.5 m)(1.4 m)

Cash From Operating Activities

(19.2 m)(27.6 m)(27 m)(28 m)

Purchases of PP&E

(1.3 m)(2 m)(6.2 m)(4.2 m)

Cash From Investing Activities

(1.3 m)(9 m)(6.7 m)(4.2 m)

Cash From Financing Activities

77.7 m436 k37.7 m52.3 m
Y, 2016

EV/EBIT

-8.1 x

EV/CFO

-8.3 x

Debt/Equity

0.4 x

Debt/Assets

0.2 x

Financial Leverage

1.7 x

Veracyte Operating Metrics

Veracyte's Facilities was reported to be 2 in FY, 2016
FY, 2016

Products

3

Patents Issued

13

Facilities

2

Veracyte Market Value History

Veracyte Online and Social Media Presence

Veracyte Company Life and Culture

You may also be interested in